Table 2.
Patient characteristics of the three risk groups in the total data set (N = 234).
| Characteristics | Low risk group (N = 153) | Intermediate risk group (N = 69) | High risk (N = 12) | P value1,2,3 |
|---|---|---|---|---|
| Age, mean (sd) | 63.1 (4.9) | 65.2 (5.4) | 63.7 (3.4) | 0.07 |
| Female | 63.1 (4.9) | 64.7 (5.6) | 64 | |
| Male | 63.8 (4.9) | 65.6 (5.4) | 63.6 (3.6) | |
| Sex, N (%) | 0.04 | |||
| Female | 71 (46%) | 29 (42%) | 1 (8%) | |
| Male | 82 (54%) | 40 (58%) | 11 (92%) | |
| Smoking, N (%) | 0.43 | |||
| No | 66 (43%) | 31 (45%) | 3 (25%) | |
| Yes | 87 (57%) | 38 (55%) | 9 (75%) | |
| Pack-years, mean (sd) | 63.2 (23.8) | 66.5 (23.9) | 74.0 (26.7) | 0.95 |
| FH of lung cancer | 0.49 | |||
| No | 115 (75%) | 47 (68%) | 8 (67%) | |
| Yes | 38 (25%) | 22 (32%) | 4 (33%) | |
| Self-reported history of COPD | 0.19 | |||
| No | 140 (92%) | 59 (86%) | 12 (100%) | |
| Yes | 13 (8%) | 10 (14%) | 0 (0%) | |
| Histology | 0.27 | |||
| Adenocarcinoma-BAC4 | 91 (59%) | 36 (52%) | 3 (25%) | |
| Squamous | 26 (17%) | 13 (19%) | 5 (42%) | |
| Small cell | 5 (3%) | 4 (6%) | 1 (8%) | |
| Other NOS | 31 (20%) | 16 (23%) | 3 (25%) | |
| Treatment | 0.13 | |||
| Surgical | 125 (82%) | 50 (72%) | 7 (58%) | |
| Chemotherapy/Other | 13 (8%) | 7 (10%) | 1 (8%) | |
| Radiation therapy | 15 (10%) | 12 (17%) | 4 (33%) | |
| Staging | 0.001 | |||
| Early stage (I and II) | 123 (80%) | 52 (75%) | 4 (33%) | |
| Late stage (III and IV) | 30 (20%) | 17 (25%) | 8 (67%) | |
| Baseline screening | 0.06 | |||
| Positive (T0+) | 111 (73%) | 41 (59%) | 6 (50%) | |
| Negative (T0−) | 42 (27%) | 28 (41%) | 6 (50%) | |
| 2.5-year overall survival rate, % | < 0.001 | |||
| Training | 89% | 63% | 10% | |
| Test Cohort | 68% | 78% | 50% | |
| 5-year overall survival rate, % | < 0.001 | |||
| Training | 77% | 41% | n/a | |
| Test Cohort | 51% | 73% | n/a |
Abbreviations: sd = standard deviation; FH = family history; Pack-years = packs smoked/day x years smoked; COPD = chronic obstructive pulmonary disease; NOS = not otherwise specified;
1 P-value obtained from Chi-squared for categorical variables.
2 P-value obtained from Anova for continuous variables.
3 P-value obtained from Log-rank for survival variables.
4 BAC and adenocarcinoma were combined into one group.